Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Genevive, Hernandez"'
Autor:
Monica E. Susilo, Chi‐Chung Li, Kapil Gadkar, Genevive Hernandez, Ling‐Yuh Huw, Jin Y. Jin, Shen Yin, Michael C. Wei, Saroja Ramanujan, Iraj Hosseini
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 7, Pp 1134-1148 (2023)
Abstract Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we leverage a previously
Externí odkaz:
https://doaj.org/article/2bc7d8bf72c444f492e191b7c0cbf612
Autor:
Kevin C. Hart, Daniel Santos, Deepal Pandya, Rong Deng, Keyu LI, Yinghui Guan, Genevive Hernandez, Thomas Manley, Maya K. Leabman, Paul R. Hinton, Liqin Liu, Angus M. Sinclair, Albert F. Candia, Stephen F. Carroll, Bruce A. Keyt, Maya F. Kotturi
Publikováno v:
HemaSphere, Vol 7, p e630565c (2023)
Externí odkaz:
https://doaj.org/article/eec65130efac469185c57723fcdf2227
Autor:
Kevin B. Walsh, Jeong M. Kim, Jovencio Borneo, Vincent Javinal, Aurelie Herault, Rajiv Jesudason, Genevive Hernandez, Judy Mak, Patricia E. de Almeida
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235e4e725cc5aa297c65f359b53e0f02
https://doi.org/10.1158/2326-6066.c.6550410
https://doi.org/10.1158/2326-6066.c.6550410
Autor:
Kevin B. Walsh, Jeong M. Kim, Jovencio Borneo, Vincent Javinal, Aurelie Herault, Rajiv Jesudason, Genevive Hernandez, Judy Mak, Patricia E. de Almeida
Supplementary tables 1-4 and supplementary figures 1-8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c71a4032796d19e9a2c56f6d9a9408
https://doi.org/10.1158/2326-6066.22543803.v1
https://doi.org/10.1158/2326-6066.22543803.v1
Autor:
Monica E. Susilo, Chi‐Chung Li, Kapil Gadkar, Genevive Hernandez, Ling‐Yuh Huw, Jin Y. Jin, Shen Yin, Michael C. Wei, Saroja Ramanujan, Iraj Hosseini
Publikováno v:
Clinical and Translational Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d91ee784d08a87c980b667cbfcca2c6c
https://doi.org/10.1111/cts.13501
https://doi.org/10.1111/cts.13501
Autor:
Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combinat
Externí odkaz:
https://doaj.org/article/6805535216ff4aaca60ddedaf5252687
Autor:
Mélanie Desbois, Thierry Giffon, Poonam Yakkundi, Sivani Pandey, Rodnie Rosete, Daniel Machado, Marigold Manlusoc, Susan Calhoun, Tasnim Kothambawala, Jey Ananta, Kristina Koyama, Yuan Cao, Dean Ng, Tomas Miranda-Katz, Avneesh Saini, Abhinav Jain, Hongjun Yue, Yang Cai, Miho Oyasu, Liz Bogaert, Roel Funke, Genevive Hernandez, Denise Nagata, Maya Leabman, Eric Humke, Stephen Carroll, Beatrice Wang, Bruce Keyt, Angus Sinclair, Maya Kotturi
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef3337c969ab061ff5e16b462458bf94
https://doi.org/10.1136/jitc-2022-sitc2022.1215
https://doi.org/10.1136/jitc-2022-sitc2022.1215
Autor:
Catherine Diefenbach, Won Seog Kim, Chan Cheah, Ajay K. Gopal, Philippe Armand, Ian Flinn, Gareth P. Gregory, Sung-Soo Yoon, Loretta Nastoupil, Jennifer Lue, Vincent Ribrag, Javier Briones, Antonio Salar-Silvestre, Anna Sureda-Balari, Matthew Ku, Hans Cruz, Paul Thaler, Ibrahim Qazi, Rachel Wei, Maya Leabman, Genevive Hernandez, Iris Sison, Elizabeth Budde
Publikováno v:
Cancer Research. 83:CT052-CT052
Background: Recent advances in the treatment of non-Hodgkin lymphoma (NHL) have transformed the landscape and provided significant benefits to patients. Novel agents that target CD19 and CD20 on B cells, such as bispecific T-cell engagers and chimeri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b50ab6cc884d3e74c23f7f7148b08d2b
https://doi.org/10.1158/1538-7445.am2023-ct052
https://doi.org/10.1158/1538-7445.am2023-ct052
Autor:
Miho Oyasu, Angus M. Sinclair, Haben Ghermazien, Genevive Hernandez, Thomas Manley, Maya K. Leabman, Stephen F. Carroll, Bruce A. Keyt, Maya F. Kotturi
Publikováno v:
Cancer Research. 83:4120-4120
Imvotamab (IGM-2323) is an engineered high-affinity, high-avidity bispecific anti-CD20 IgM antibody T cell engager (TCE) that is currently being studied as monotherapy in a Phase 1/2 clinical trial for relapsed/refractory non-Hodgkin’s lymphoma (NH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48edba407be9da7e5d2588e1383a93d0
https://doi.org/10.1158/1538-7445.am2023-4120
https://doi.org/10.1158/1538-7445.am2023-4120
Autor:
Kevin Walsh, Aurelie Herault, Genevive Hernandez, Patrícia de Almeida, Judy Mak, Jeong M. Kim, Rajiv Jesudason, Vincent Javinal, Jovencio Borneo
Publikováno v:
Cancer Immunology Research. 8:806-818
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bc6b07a7032555f678c5771e7435df3
https://doi.org/10.1158/2326-6066.cir-19-0360
https://doi.org/10.1158/2326-6066.cir-19-0360